Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non-Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database

被引:95
|
作者
Osarogiagbon, Raymond U. [1 ]
Yu, Xinhua [2 ]
机构
[1] Boston Baskin Canc Fdn, Baptist Canc Ctr, Multidisciplinary Thorac Oncol Program, Memphis, TN USA
[2] Univ Memphis, Sch Publ Hlth, Dept Epidemiol & Biostat, Memphis, TN 38152 USA
关键词
Non-small-cell lung cancer; Surgical resection; Mediastinal lymph nodes; Quality of care; Outcome of care; Staging; LONG-TERM SURVIVAL; PULMONARY RESECTION; SURGICAL RESECTION; SURGEON SPECIALTY; RANDOMIZED-TRIAL; LYMPHADENECTOMY; OUTCOMES; NUMBER; CLASSIFICATION; DISSECTION;
D O I
10.1097/JTO.0b013e31827457db
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pathologic nodal stage is the key prognostic factor in resectable non-small-cell lung cancer (NSCLC). Mediastinal lymph node (MLN) metastasis connotes a poor prognosis. Yet, some NSCLC resections exclude MLN examination. Methods: We analyzed U.S. Surveillance, Epidemiology, and End Results program data from 1998 to 2002 to quantify the long-term survival impact of failure to examine MLN in resected NSCLC. We used Kaplan-Meier methods to compare the unadjusted survival difference between patients with, and without, MLN examination, and Cox proportional hazards and competing risk models to serially adjust for the impact of risk factors on survival differences. Results: Sixty-two percent of patients with pathologic N0 or N1 NSCLC had no MLN examined. Overall 5-year survival rates were 52% for those with, versus 47% for those without, MLN examination; lung cancer-specific survival rates were 63% versus 58% respectively (p < 0.001); nonlung cancer mortality was identical between cohorts. Adjusting for potential confounders, MLN examination was associated with a 7% reduction in all-cause mortality (hazard ratio, 0.93; confidence interval, 0.88-0.97; p = 0.002), and 11% reduction in lung cancer-specific mortality (hazard ratio, 0.89; 95% confidence interval, 0.84-0.95; p < 0.001) rates. The excess risk in 1 year's cohort of U. S. lung resections was 3150 lives over 5 years. Conclusions: Failure to examine MLN was a common practice in MLN-negative NSCLC resections, which significantly impaired long-term survival. Efforts to understand the etiology of this quality gap, and measures to eliminate it, are warranted.
引用
收藏
页码:1798 / 1806
页数:9
相关论文
共 50 条
  • [1] Mediastinal lymph node examination and survival in resected early-stage non-small cell lung cancer in the Surveillance, Epidemiology, and End Results (SEER) database
    Osarogiagbon, Raymond U.
    Yu, Xinhua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Risk factors for mediastinal lymph node metastases in early-stage non-small-cell lung cancer and prediction model establishment
    Tang, Yubo
    Garu, A.
    Chen, Xiao
    Guan, Ziyun
    Cai, Xingdong
    Huang, Huaxing
    Xitao, Linghu
    Tang, Kejing
    Dong, Yong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (12): : 5952 - 5964
  • [3] SURVIVAL IN EARLY-STAGE NON-SMALL-CELL LUNG-CANCER
    NESBITT, JC
    PUTNAM, JB
    WALSH, GL
    ROTH, JA
    MOUNTAIN, CF
    ANNALS OF THORACIC SURGERY, 1995, 60 (02): : 466 - 472
  • [4] Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
    Christopher G Azzoli
    Nature Clinical Practice Oncology, 2005, 2 : 552 - 553
  • [5] Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
    Azzoli, CG
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (11): : 552 - 553
  • [6] Postoperative radiotherapy for stage II or III non-small-cell lung cancer using th surveillance, epidemiology, and end results database
    Lally, Brian E.
    Zelterman, Daniel
    Colasanto, Joseph M.
    Haffty, Bruce G.
    Detterbeck, Frank C.
    Wilson, Lynn D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 2998 - 3006
  • [7] VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
    Heist, Rebecca Suk
    Zhai, Rihong
    Liu, Geoffrey
    Zhou, Wei
    Lin, Xihong
    Su, Li
    Asomaning, Kofi
    Lynch, Thomas J.
    Wain, John C.
    Christiani, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 856 - 862
  • [8] Lobe-specific lymph node dissection in early-stage non-small-cell lung cancer: An overview
    Peng, Lei
    Shang, Qian-Wen
    Deng, Han-Yu
    Liu, Zhen-Kun
    Li, Wen
    Wang, Yun
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 683 - 687
  • [9] Relationship of number of resected lymph nodes in early-stage non-small cell lung cancer (NSCLC) and survival
    Berardi, R.
    Onofri, A.
    Savini, A.
    Caramanti, M.
    Chiorrini, S.
    Santinelli, A.
    Brunelli, A.
    Zuccatosta, L.
    Mazzanti, P.
    Pierantoni, C.
    Scartozzi, M.
    Sabbatini, A.
    Gasparini, S.
    Cascinu, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer
    Cao, Weibo
    Tang, Quanying
    Zeng, Jingtong
    Jin, Xin
    Zu, Lingling
    Xu, Song
    CANCERS, 2023, 15 (18)